Paxman AB ( (PXMBF) ) has released its Q3 earnings. Here is a breakdown of the information Paxman AB presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paxman AB, a leader in scalp cooling technology, is focused on preventing chemotherapy-induced alopecia and neuropathy with innovative solutions for cancer patients worldwide. In its latest earnings report, Paxman showed a 6% increase in sales, reaching 64.8 MSEK in Q3 2024. While net results decreased compared to the previous year, the company achieved positive net cash flow and maintained strong recurring income. Noteworthy developments include a contract with the U.S. Department of Veterans Affairs and the issuance of CPT Category I codes, which are expected to enhance the adoption of Paxman’s insurance-based billing model. Looking ahead, management remains optimistic about continued growth, particularly in the U.S. market, and is committed to advancing its research and development efforts to support sustainable expansion.